Repligen, a global life sciences company, develops and commercializes innovative bioprocessing technologies that increase efficiencies and flexibility in biotherapeutic manufacturing. As leaders in filtration, chromatography systems, process analytics and fluid management, we are committed to inspiring advances in bioprocessing. We are a trusted partner in the production of monoclonal antibodies, recombinant proteins, vaccines as well as cell and gene therapies. Named one of the fastest growing biotech companies in the USA, the majority of our 18 manufacturing sites are located in the United States (California, Massachusetts, New Jersey, New Hampshire, New York and Texas). Outside the United States, we have manufacturing sites in Estonia, France, Germany, Ireland, the Netherlands, and Sweden. | Repligen, a global, bioprocessing-focused life sciences company, provides innovative solutions for the advancement of biotherapeutic manufacturing. Experts in filtration, chromatography systems, process analytics, fluid management, and proteins, Repligen is a trusted partner serving the development and manufacture of a wide range of biologics, including cell and gene therapies, mRNA, monoclonal antibodies (mAbs), antibody–drug conjugates (ADCs), bispecific antibodies, and fusion proteins. Headquartered in Waltham, Massachusetts, USA, Repligen operates across 22 sites, including locations in the United States, Europe, and the Asia-Pacific region. | Inspiring advances in bioprocessing, Repligen is a trusted partner in process intensification, pre-packed chromatography and single-use filtration. Focused on cost and process efficiencies, our people and our technologies help meet critical bioproduction demands worldwide. As the recognized global leader in Protein A manufacturing, Repligen’s Protein A affinity ligands are routinely used to purify most of the world’s monoclonal antibodies.
Cytomos
Cytomos is a cutting edge biotool company revolutionising predictive cell analytics, using the physics of the cell to predict biology. Our proprietary platform, Celledonia® powered by AuraCyt® uniquely predicts cell behaviour by capturing a digital fingerprint of every cell — delivering rapid, high-resolution insights into cell health, phenotype, and function. Celledonia® offers intrinsic, label-free cell analysis at the press of a button, enabling faster, more reliable decisions across research, development, and manufacturing, unveiling a new dimension of cellular understanding. Cytomos provides technology that accelerates discovery, development and scale-up in areas including advanced therapies, cell line development, immunotherapies, differentiation competent cells and biologics. Our mission is to redefine how we understand and control living cells. Celledonia® is a benchtop cell analyser which detects cell features for which there are no biomarkers and provides predictive insights into how those cells will behave during processing. In short, it lets you see what’s coming — before it happens. That predictive power has huge implications for biomanufacturing: faster process optimisation, improved product consistency, and a deeper understanding of what drives cellular performance, quickly. We don’t simply hand over the technology and wish you luck; we work alongside you, integrating the system into your processes to ensure you see the full benefits. We have a dedicated team of scientists and data analysts at our Edinburgh laboratories, who collaborate closely with your teams both in the lab and remotely. Our goal is to make this revolutionary technology both accessible and impactful.